WeVote
Log In

Bill

Bill

SR 30

Recognizing 80th anniversary of Claude Worthington Benedum Foundation

2025 Regular Session Introduced by Robbie Morris and 1 co-sponsor

Designates May 4-10, 2025 as Tardive Dyskinesia Awareness Week to raise awareness, encourage screening, reduce stigma, and educate providers and patients (nonbinding).

Completed legislative action
0
WeVote Research Nonpartisan
Bill Summary · SR 30

Summary — SR 30: Designation of Tardive Dyskinesia Awareness Week (May 4–10, 2025)

Status: Adopted by the Senate (enrolled). Adopted April 22, 2025.
Primary sponsors (enrolled version): Senators Sylvia Santana, Jeremy Geiss, and Suzi McMorrow.

Purpose and intent

SR 30 is a non‑binding Senate resolution that designates the week of May 4–10, 2025, as “Tardive Dyskinesia Awareness Week.” Its purpose is to raise public and clinical awareness of tardive dyskinesia (TD), encourage routine screening and early detection, reduce stigma for people experiencing TD, and promote education for health care providers, patients, and caregivers about diagnosis and treatment options.

Key provisions

  • Officially designates May 4–10, 2025 as Tardive Dyskinesia Awareness Week.
  • Describes TD as uncontrollable, abnormal, repetitive movements (face, torso, limbs) commonly associated with prolonged antipsychotic medication use.
  • Identifies higher‑risk groups: adults older than 55, Black individuals, women, people with mood or substance use disorders, those with intellectual disabilities or central nervous system injuries, and persons with high cumulative antipsychotic exposure.
  • Cites epidemiology and clinical concerns: an estimated 800,000 U.S. adults live with TD and roughly 60% of them remain undiagnosed.
  • Encourages routine TD screening in line with American Psychiatric Association clinical guidelines and urges patients experiencing abnormal movements to consult health care providers.
  • Notes that FDA‑approved treatments exist that may improve symptom management and quality of life.
  • Calls for education and awareness efforts directed at providers, patients, and care partners to align care with clinical best practices.

Who is affected

  • Primarily informational and awareness impact on: patients receiving antipsychotics, their families and care partners, psychiatrists, primary care clinicians, allied health professionals, patient advocacy organizations, and public health communicators.
  • No statutory, regulatory, or funding changes are made; the resolution is symbolic and advisory rather than binding.

Procedural and timeline notes

  • Adopted by the Senate (enrolled) on April 22, 2025; specifies the awareness week dates (May 4–10, 2025).
  • As a Senate resolution, it does not create new legal obligations, appropriations, or changes to clinical practice standards, but may prompt voluntary educational campaigns and screening initiatives by health systems or advocacy groups.

Potential impact

  • Raises visibility of TD and may increase screening, diagnosis, referrals, and patient‑provider conversations about treatment risks and options.
  • May help reduce stigma and encourage uptake of FDA‑approved TD treatments and supportive services.
  • No direct fiscal impact or regulatory authority—effects depend on follow‑up actions by health providers, advocacy organizations, and public health entities.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.